IMUGENE is one of several Western Australian companies to receive a grant from the Federal Government’s Biotechnology Innovation Fund.
It has received $250,000 towards its work on developing an avian influenza vaccine for the commercial poultry industry.
The BIF grants varied from $82,000 to $250,000.
Eight other WA companies received grants through the BIF program.
Those companies were:
Agri Biotech received $224,125 for an antibody-based treatment for burns;
Medic Vision gaining $250,000 for the development of a virtual reality surgical simulation;
Bone Medical receiving $250,000 for the development of an oral hormone for the prevention and treatment of osteoporosis;
Ag-ID gaining $248,200 for a DNA detection and analysis process for livestock;
RXNet receiving $241,080 to develop a non-invasive blood glucose measuring device;
Phylogica getting $250,000 towards pre-clinical trialing of therapeutic leads for stroke;
Stirling Products receiving $239,275 for the commercialisation of its merino lamb growth hormone agent; and
Inner Vision Biometrics gaining $212,736 for its non-invasive magnetic resonance imaging test for liver fibrosis.